The effects of JAK inhibitor therapy upon novel markers of thrombosis In myeloproliferative neoplasms

Haematologica. 2015 Sep;100(9):e348-50. doi: 10.3324/haematol.2015.128918. Epub 2015 Jun 18.
No abstract available

Keywords: Janus kinases; blood platelets; primary myelofibrosis; thrombosis.

Publication types

  • Clinical Trial
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aspirin / administration & dosage
  • Biomarkers / blood
  • Female
  • Hematologic Neoplasms*
  • Humans
  • Janus Kinase 2* / antagonists & inhibitors
  • Janus Kinase 2* / blood
  • Janus Kinase 2* / genetics
  • Male
  • Middle Aged
  • Nitriles
  • Polycythemia Vera* / blood
  • Polycythemia Vera* / drug therapy
  • Polycythemia Vera* / genetics
  • Pyrazoles / administration & dosage*
  • Pyrimidines
  • Pyrrolidines / administration & dosage*
  • Sulfonamides / administration & dosage*
  • Thrombocythemia, Essential* / blood
  • Thrombocythemia, Essential* / genetics
  • Thrombosis* / blood
  • Thrombosis* / drug therapy
  • Warfarin / administration & dosage

Substances

  • Biomarkers
  • Nitriles
  • Pyrazoles
  • Pyrimidines
  • Pyrrolidines
  • Sulfonamides
  • Warfarin
  • fedratinib
  • ruxolitinib
  • JAK2 protein, human
  • Janus Kinase 2
  • Aspirin